Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Chemotherapy Added to RT Prolongs FFS in Stage III Endometrial Cancer
30 března, 2021 7:25 pmJune 4, 2017 A combination of chemotherapy and radiotherapy prolonged 5-year failure-free survival (FFS) among patients with high-risk, stage...
Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer
30 března, 2021 2:25 amMeeting: 2017 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5506 Citation: J Clin Oncol 35, 2017...
Trend in OS Benefit with Cediranib for Ovarian Cancer: ICON6 Results
30 března, 2021 1:57 amJune 3, 2017 Median overall survival (OS) was 7.4 months longer among patients with platinum-sensitive, relapsed ovarian cancer who...
A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma
30 března, 2021 1:24 amMeeting: 2017 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5505 Citation: J Clin Oncol 35, 2017...
No Increase in Recurrence-Free Survival with Combined Regimen for Stage III/IVA Endometrial Cancer
30 března, 2021 1:01 amJune 3, 2017 A combined modality regimen did not increase recurrence-free survival (RFS) in patients with optimally debulked stage...
LION: Lymphadenectomy in ovarian neoplasms – A prospective randomized AGO study group led gynecologic cancer intergroup trial
30 března, 2021 12:58 amMeeting: 2017 ASCO Annual Meeting Track: Oral Abstract Session Abstract number: 5500 Citation: J Clin Oncol 35,...
LION Findings Endorse Omitting Lymphadenectomy in Node-Negative Advanced Ovarian Cancer
30 března, 2021 12:53 amAccording to results of the large randomized LION Gynecologic Cancer Intergroup trial, routine pelvic and para-aortic lymphadenectomy offers no benefit...
NOVINKY Z ASCO – GYNEKOLOGICKÉ MALIGNITY
30 března, 2021 12:43 amTaké na letošním ročníku konference Americké společnosti klinické onkologie (ASCO) byl věnován prostor prezentacím zaměřeným na gynekologické nádory. Zaznělo několik sdělení, která...
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER
30 března, 2021 12:39 amMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer – Local/Regional/Adjuvant Abstract number: 501 Citation: J Clin Oncol...
A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03)
30 března, 2021 12:31 amMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy Abstract number: 507 Citation: J Clin Oncol 35,...